αGalCer-RBD
αGalCer-RBD is a self-adjuvanting vaccine candidate that conjugates the iNKT cell agonist α-Galactosylceramide to the SARS-CoV-2 RBD domain. It induces robust immunity by generating RBD-specific, cytokine-producing T cells, as demonstrated in preclinical in vivo studies against SARS-CoV-2 and its variants.
Product Specifications
Field of Research
Infectious Disease & Virology
Molecular Formula
C60H118N4O14
Molecular Weight
1119.6
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog